Prophase Labs ( (PRPH) ) has released its Q3 earnings. Here is a breakdown of the information Prophase Labs presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ProPhase Labs, Inc. is a biotech and genomics company engaged in developing and commercializing novel drugs, dietary supplements, and diagnostics, with a focus on genomics sequencing technologies and consumer products. In its latest earnings report, ProPhase Labs highlighted a challenging financial quarter, with a net loss of $6.8 million for the three months ending September 30, 2025, compared to a loss of $6.6 million in the same period last year. The company’s revenues declined to $883,000 from $1.4 million a year ago, reflecting a decrease in COVID-19 diagnostic testing activities. Despite the financial setbacks, ProPhase Labs continues to advance its strategic initiatives, including the commercialization of its BE-Smart™ Esophageal Pre-Cancer Diagnostic Screening Test and the expansion of its genomics businesses. The company has also made significant strides in its genomics offerings through Nebula Genomics and DNA Complete, providing comprehensive genome sequencing services directly to consumers. Looking ahead, ProPhase Labs remains focused on recovering unpaid insurance claims from its discontinued COVID-19 testing operations and advancing its genomics and diagnostic product lines, with plans for broader commercialization in the coming year.